QDEL IR Day Presentation Final 2022.12.13

December 13, 2022
QuidelOrtho
Investor Day
Welcome and
Cautionary Language
© 2022. All Rights Reserved. 3
Forward-Looking Statements
Forward-Looking Statements: The presentations of QuidelOrtho Corporation (“QuidelOrtho” or the “Company”) during today’s Investor Day contain “forward-
looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements and other forward-looking
statements in these presentations by words such as “may,” “will,” “would,” “expect,” “anticipate,” “believe,” “estimate,” “plan,” “intend,” “continue” or similar
words, expressions or the negative of such terms or other comparable terminology. These statements include, but are not limited to, the benefits and results of
the business combination by and among QuidelOrtho, Quidel Corporation (“Quidel”), Ortho Clinical Diagnostics Holdings plc (“Ortho”) and certain other entities
(the “Combinations”) and integration of the businesses of Quidel and Ortho including QuidelOrtho’s execution of cost and revenue synergies, commercial,
integration and other strategic goals, future financial and operating results, future plans, objectives, strategies, expectations and intentions and other statements
that are not historical facts. Such statements are based on the beliefs and expectations of QuidelOrtho’s management as of today and are subject to significant
risks and uncertainties. Actual results may differ significantly from those set forth or implied in the forward-looking statements. The following factors, among
others, could cause actual results to differ from those set forth or implied in the forward-looking statements: the challenges and costs of integrating,
restructuring and achieving anticipated synergies as a result of the Combinations; the ability to retain key employees; and other economic, business, competitive
and/or regulatory factors affecting the business of QuidelOrtho generally. Additional risks and factors are identified under “Risk Factors” in QuidelOrtho’s
Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the “Commission”) on August 5, 2022, and subsequent reports filed with the
Commission. You should not rely on forward-looking statements as predictions of future events because these statements are based on assumptions that may
not come true and are speculative by their nature. QuidelOrtho has no obligation to update any of the forward-looking information or time-sensitive information
included in these presentations, whether as a result of new information, future events, changed expectations or otherwise, except as required by law. All forward-
looking statements are based on information currently available to QuidelOrtho and speak only as of the date hereof.
Supplemental Combined Financial Measures and Non-GAAP Financial Measures

Supplemental Combined Financial Measures: Certain presentations contain unaudited supplemental combined financial information (“Supplemental Combined Information”)
that gives effect to the Combinations as if Quidel and Ortho had been combined for the applicable periods. The Supplemental Combined Information presented is based on the
historical financial statements of Quidel and Ortho with reclassification adjustments only and do not include all of the pro forma adjustments required under Regulation S-X
Article 11 or Accounting Standards Codification 805, Business Combinations (“ASC 805”). This Supplemental Combined Information is provided for illustrative purposes only, may
be updated in the future, and is not necessarily, and should not be assumed to be, indicative of the Company’s expected results of operations or financial position that would
have been achieved had the Combinations been completed as of the dates indicated or that may be achieved in any future period. The Supplemental Combined Information
should be considered supplemental to, and not as a substitute for, pro forma financial information prepared in accordance with Regulation S-X Article 11 or ASC 805 and should
be read in conjunction with the information contained in the sections entitled the “Combinations,” “Management’s Discussion and Analysis of Financial Condition and Results of
Operations of Ortho” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations of Quidel” in QuidelOrtho’s joint proxy statement/prospectus
(the "Joint Proxy Statement/Prospectus“) filed with the Commission on April 11, 2022, and the historical consolidated financial statements and related notes appearing elsewhere
in, or incorporated into, the Joint Proxy Statement/Prospectus, and the Company’s subsequent reports filed with the Commission. The Company’s actual results of operations and
financial position will differ, potentially significantly, from the Supplemental Combined Information reflected in these presentations as a result of the methodology used to
prepare the Supplemental Combined Information as well as a variety of factors including, but not limited to, the effect of certain expected financial benefits of the Combinations
(such as revenue and cost synergies), the anticipated costs to achieve these benefits (including the cost of integration activities), tax impacts and changes in operating results
following the date of these presentations.
Non-GAAP Financial Measures: Certain presentations contain financial measures including, but not limited to, “constant currency revenue growth,” “adjusted diluted EPS,”
“adjusted EBITDA,” “adjusted EBITDA margin,” “supplemental combined revenue,” “supplemental combined adjusted diluted EPS,” “supplemental combined adjusted EBITDA”
and “supplemental combined adjusted EBITDA margin,” which are considered non-GAAP financial measures under applicable rules and regulations of the Commission. These
non-GAAP financial measures should be considered supplemental to, and not a substitute for, financial information prepared in accordance with U.S. generally accepted
accounting principles (“GAAP“). “Adjusted EBITDA” and “adjusted diluted EPS” eliminate impacts of certain non-cash, unusual or other items that the Company does not consider
indicative of its ongoing operating performance, and the Company generally uses these non-GAAP financial measures to facilitate management’s financial and operational
decision-making including evaluation of the Company’s historical operating results and comparison to competitors’ operating results. The Company believes that “supplemental
combined revenue,” “supplemental combined adjusted diluted EPS,” “supplemental combined adjusted EBITDA” and “supplemental combined adjusted EBITDA margin” provide
helpful Supplemental Combined Information to assist management and investors in evaluating the Company’s adjusted operating results as if Quidel and Ortho had been
combined for the applicable periods. The Company’s definitions of these non-GAAP measures may differ from similarly titled measures used by others. These non-GAAP financial
measures reflect an additional way of viewing aspects of the Company’s operations that, when viewed with GAAP results and the reconciliations to corresponding GAAP financial
measures, may provide a more complete understanding of factors and trends affecting the Company’s business. Because non-GAAP financial measures exclude the effect of
items that will increase or decrease the Company’s reported results of operations, management strongly encourages investors to review the Company’s consolidated financial
statements and reports filed with the Commission in their entirety. Reconciliations of the non-GAAP financial measures, including the non-GAAP Supplemental Combined
Information, to the most directly comparable GAAP financial measures are included in the Appendix to these presentations as applicable.
QuidelOrtho
Transforming the Power
of Diagnostics
Douglas Bryant
President & Chief Executive Officer
Objectives for Today
• Strong Business: We are an in vitro diagnostics leader with growth opportunities

in our Point of Care, Molecular Diagnostics, Labs and Transfusion Medicine businesses
• Executing on Integration: Integration is going smoothly, the two organizations
are meshing well and cost synergies are ahead of target
• Multiple Growth Drivers: We have multiple revenue drivers that are differentiated
and in attractive growth segments of the diagnostics market
• Strong Financial Profile: COVID-19 story has been de-risked, we have a low-
leverage balance sheet and strong outlook for revenue, margins, EPS and cash flow
• Experienced Management Team: Highly experienced management with proven
track records of success to accelerate growth and drive innovation
Who You’ll Hear From Today
Bryan Hanson
Pat Klein Werner Kroll, PhD
Labs
Chief Administrative Senior Vice President
Business Unit Leader
Officer Research & Development
Bill Ferenczy
Rob Bujarski Point of Care Michael Iskra
Executive Vice Business Unit Leader Executive Vice
President & Chief President & Chief
Operating Officer Commercial Officer
Andrew Corkum
Transfusion Medicine
Joe Busky
Chief Financial Officer
Tammi Ranalli, PhD

Molecular Diagnostics
Strategic Intent:
Transforming the Power of Diagnostics Into a Healthier Future for All
Integration and Culture Unite the people, processes and products of QuidelOrtho to accelerate
innovation, expand commercial reach and improve patient outcomes across the healthcare continuum
within a culture of speed, happiness and engagement.
Product Innovation Invest in R&D to expand diagnostic testing platforms and menus across the
business portfolios and secure global clearances for rollout of innovative instruments and assays.
Commercial Excellence Lead the industry in customer satisfaction and maximize revenue pull-through
with superior quality, differentiated services and steadfast focus on Retain, Grow, Win strategies.
Operational Excellence Integrate global operations and manage supply chains, which are expected to
deliver cost synergies, competitive advantages and revenue targets.
Capital Deployment Leverage strong balance sheet and cash generation to evaluate longer-term
growth investments to potentially increase operational capacity, capture a larger share of the market
and/or generate more revenue.
9
Q&A
Imagining
a Better Future … Together
Pat Klein
Chief Administrative Officer
To Deliver Our Integration Goals, Our Program Is Structured to …
RETAIN & DRIVE HARMONIZE &

ENGAGE OUR PRODUCT ENHANCE OUR
PEOPLE INNOVATION & PROCESSES &
COMMERCIAL SYSTEMS
EXCELLENCE
Overall Integration Goal Is to Create a Company of Purpose That Enriches and

Saves Lives With A Culture That Promotes Employees First and Prioritizes
Actions That Support Happy, Inspired and Engaged Team Members
Future State
Ongoing Business
Interim State
Integration Journey Key Milestones • Complete Q4’24
• Complete Q1’23
• Launched name, logo • Implement commercial
and brand expression priorities and region-specific
90 Days GTM plans
• Completed employee survey
• Establish compliance and
• Announced business • Enabling commercial governance cadence
leaders, operating priorities and region-specific
30 Days model and regional go-to-market (GTM) plans • Strengthen operating model
• Established IMO, leadership • Completed organization • Realize value-creation
integration leads and • Launched technology and structures technologies
priorities systems gap analysis • Continue above 88% • Realize cost savings and
• Assessed operational • Assessed change employee retention rate revenue synergies
alignment and planning readiness stakeholder • Activate QuidelOrtho culture,
May
• Announced engagement core behaviors and DEI+E
Close executive team initiatives
• Activated 15 functional
• Identified critical processes, workstreams • Continue communications
policies and technologies & change management
Cultural Statement
The QuidelOrtho Way

Imagining a Better Future … Together
We believe we are better together, in a team where everyone is
welcome to thrive and where diverse perspectives are encouraged
and authenticity is expected.
We are committed to our employees FIRST and we prioritize

actions that support happy, inspired and engaged team members.
We operate with speed by focusing on the few things that matter

most. We believe in execution excellence, having courage to take
risks and always striving to be better.
We give back to our communities and build enduring customer

relationships. We imagine a better future, explore ideas and build
life-changing technologies. Together, we enrich and save lives.
We are QuidelOrtho
Where We Are
Our global footprint is comprised of 6,000+ employees in 130+ countries
EMEA
1,318
NA
4,207
Greater
China
479
Market serviced
by QuidelOrtho
LATAM ASPAC*
364 609
Headquarters
Manufacturing and Distribution
Regional Offices
*ASPAC includes Japan

How Our Employees Are Feeling

Our employee survey results indicate positive employee sentiment around engagement,
retention and workplace experience
Global Participation Trending Positive: My Manager
Above Threshold
+75% 71%
• Intent to Stay – 81%
• Engagement – 78%
• Connectedness – 77%
• Career Experience – 75%
Overall Favorability Trending Positive: Agility

Trending Moderate
70% 71%
• Job Satisfaction – 69%
• Innovation – 65%
Building on Positive
Momentum Into 2023
17
Q&A
Setting the Strategic
Business Direction
Rob Bujarski
Executive Vice President
& Chief Operating Officer
Our World Is Changing
9.7B people
will inhabit the BY
2.520BILLION
50 THERE 5.07 BILLION
4 .6 BILLION
world in 20502 WADDITIONAL
ILL BE A N PEOPLE
PEOPLEARE A RE
APEOPLE
DDITIONA L
WILL CONNECTED TO
CONNECTED TO 6 in 10 adults
LIVE IN CITIES
2.5 BILLION THE INTERNET
THE INTERNET in U.S. have a
Leads to PEOPLE chronic disease3
15,000 more
diseases going
between species BY 20 50 ,
in the next 50 BYBY
2100, GLOBAL
210 0 , GLOBA L A VERAOF
18.6% GE TOTAL
LIFE
years1 TEMPERATURES
TEMPERA TURES ARE POPULATION
EXPECTANCYIS
PROJECTED TO RISE
A RE PROJECTED AGED
W ILL 65 OR OLDER
INCREASE
BYRISE
5° CELSIUS
BY 4 CELSIUS BY 6 .5 YEARS
BY 20 50 , 1/ 3 OF THE
THERE
BY 2050, THERE W39% OF
ORLD’S
W ILL BE
WILL BE 2X2X AAS
S ADULTSTION
POPULA
MA NY PEOPLE
MANY PEOPLE EXCEED AA
EXCEEDS
OVER-6
OVER 600 HEALTHY
HEA LTHY W EIGHT
WEIGHT
8484 MILLION
1/ 3+ OF MILLION
PEOPLE
Source:
1 in 3FEEL
A DULTS
ADULTS PEOPLE
HA VE BEEN
1. Natural History Museum LONELY FEEL HAVE BEEN
FORCIBLY
2. CHRON: United Nations LONELY
FORCIBLY
DISPLA CED
3. CDC
DISPLACED
Technology Is An Accelerant
91%
Of World’s Population Has A Mobile Phone 1
63%
Of World’s Population Is Connected To The Internet
2
Source: 1. Bank My Cell 2. Data Reportal

Healthcare Is Changing
Demand Resources
39%
Of the adults exceed
+50%
a healthy weight
Of the world’s population
doesn’t have access to
2x
health services2
As many people over

the age of 60 by 2050
10M
More healthcare workers
26%
will be needed by 20303
GDP spent on
healthcare by 20401
Source: 1. Deloitte Insights 2. Healthcare Radius 3. World Health Organization

Reliable real-time intelligence
has never been more critical.
70%
of clinical decisions are made from
in-vitro diagnostics (IVD) test results
1
Source: 1. MedTech Drive

Our Industry Is At An Inflection Point
DECENTRALIZED CENTRALIZED
HOME RETAIL AMBULATORY CLINICS & SPECIALTY SETTINGS HOSPITALS REFERENCE LABS
OTC Consumer-Oriented Physician Urgent Surgical Micro- Free Sexual Small-Medium Large Donor National
Self Testing Ambulatory Network
OB-GYN IDN Core Labs
Office Care Care hospital Standing ER Health Hospital Hospital Screening Reference Lab
EXPANDING FOR CONVERGENCE ACROSS CONSOLIDATING

INDIVIDUALS THE CONTINUUM FOR SYSTEMS
lines are blurring,

lower throughput capabilities are colliding higher throughput
non-expert user and solutions need to stretch expert user
38x More virtual care visits

than pre-pandemic 1 56% in healthcare M&A in 20213
10.8% 2022-2029 Projected

U.S Retail Clinic Growth 2
70% U.S. physicians employed in
hospital/corporate owned practices4
CAGR
Source: 1. Healthcare Dive 2. Fortune Business Insights 3. Fierce Healthcare 4.Healthcare Finance
QuidelOrtho Is Setup to Meet These Opportunities
Office Care Care hospital Standing ER Health Hospital Hospital Screening Reference Lab

lines are blurring,

~25% Testing Distribution ~75% Testing Distribution
Point of Care
Molecular
Labs
Chart is an approximate distribution of testing sites in the U.S. market Transfusion Medicine
Internal Analysis - Corporate Strategy & Insights
Each Business Unit Operates Within a Large Area of Opportunity

Complementary portfolios to drive increased pull-through and deeper customer relationships
Clinical Immunoassay Molecular Transfusion

Point of Care Chemistry (Central Lab) Diagnostics Medicine
$8B $9B $19B $9B $2B

Total
Addressable
Market1
Steady State
Growth2 6-8% 3-5% 6-8% 8-10% 2-4%
1. Estimated based on 2022 IQVIA Market Book

2. Steady State Growth based on management’s estimates, excluding COVID-19 revenues
Introducing Our Business Unit and R&D Executives
Bryan Hanson Bill Ferenczy Andrew Corkum Tammi Ranalli, PhD Werner Kroll, PhD
Labs Point of Care Transfusion Medicine Molecular Diagnostics Senior Vice President
Business Unit Leader Business Unit Leader Business Unit Leader Business Unit Leader Research & Development
Labs
Bryan Hanson
Labs Business Unit Leader
Diagnostics Continuum
Office Care Care Hospital Standing ER Health Hospital Hospital Screening Reference Lab

lines are blurring,

Point of Care
Molecular
Labs
Labs Business Unit
TTM Total Revenue, Ex-COVID-191 Total Installed Base Integrated Installed Base
$1.35B ~14K ~4K

+2% y/y2 +4% y/y +11% y/y
Product Lines1 Geography1 Category1

Instruments
6%
Other
5%
Other
22%
North
America
Immunoassay Clinical 52%
37% Chemistry China
58% 16% Recurring
94%
EMEA
10%
1. Excludes COVID-19-related revenue

2. Growth rates are in constant currency
Our Role
The cornerstone and catalyst for QuidelOrtho’s global expansion and growth
Labs Inflection Point: Our Expansive Product Portfolio Ensures Labs

Soaring Testing Demand in Resource Scarce Environment Can Effectively and Efficiently Access Testing
1/2
1 1
14B
Lab Tests World’s Population Lacks
Conducted Each Year Access to Diagnostic Testing
70% 25K
1 2
of Medical Estimated MT
Decisions Openings
Rely on Lab Tests in the U.S.
1. CDC, Division of Lab Systems

2. Sourced from CLPMAG.com
Lab Market Is Robust and Projected to Grow at ~4% (Clinical Chemistry)

and ~7% (Immunoassay)
Projected to Grow at 6% CAGR

Projected 5-Year CAGR
(2021-2026)
2026E 5-6%
Labs Market
Instrument Throughput 16% 10%
2021
Ultra-High 13%
>70%
75% of the 6%
75% Market
Sweet Spot
Low 12% 10% 1%

Source: Estimated based on 2022 IQVIA Market Book & internal analysis
Clinical Labs Revenue Mix vs. Market Segment Mix

Significant margin and growth opportunity by changing revenue mix
2021 CL Revenue Mix1 2021 Segment Data2
Clinical
Immunoassay Chemistry
42% 32%
Clinical
Chemistry Immunoassay
58% 68%
Strength in clinical chemistry Opportunity in larger, faster growing

underpinned by benefits in immunoassay segment with growth
dry technology in integrated installed base
1. 2021 QuidelOrtho clinical labs revenue, excluding SARS-CoV-2 assays. Does not include specialty diagnostics.
2. Sourced from IQVIA Market Book to exclude COVID-19 assay revenue
Installed Base Penetration Within Sweet Spot

90% of installed base below 1M, opportunity to expand IA throughout to drive growth
Non-Hospital Hospital Volume Annual Standalone CC Integrated Standalone IA Integrated

Integrated
Labs Labs Segment Volume 52% 29% 19% Value
Value
Ultra-High
UHV >6.0M
Nat’l/Int’l
Ref Labs
H ($4.7B)
($1.3Bn)
Large
Hospitals
4.0-6.0M 22×
2.0-4.0M 13×
Mid- to
Regional H Very-High
Ref Labs Medium ($21.5B)
Hospitals 1.0-2.0M 7×
<250K-1.0M 3×
Small H
Ind Labs Small Low
& POLs ($3.2B) <250K Baseline
Hospitals
% of Installed Base
Product Development Driving Trajectory
~2023 ~2024 ~2025 - 2030
Growth Within Higher Volume Settings Emerging Market Growth Long-Term Innovations and Expansion
Refresh VITROS Systems Low-Cost, Low-Volume Platforms

and Software IA Menu Expansion Including
Novel and Specialty Markers:
20-25 New/Refreshed Assays
Low Volume
Integrated
Continued Investment in
VITROS® 450
Informatics and Launch Clinical Chemistry System
of NGT Automation
Launch VITROS Duo, Duo+
and QuidelOrtho Hub IA Menu Expansion Including
30-35 New/Refreshed Assays
Scalable Dry Slide and Development

of Modular NGT Platform
China Localization Strategy and

New IA Assay Development
Key Takeaways
• The Labs business unit is well-positioned and differentiated in a large, growing market with
limited threat of new entrants
• We believe that VITROS has significant revenue upside due to current market position within
sweet spot and favorable revenue acceleration of IA with standalone to integrated conversion
strategy
• Near-term product launches and investments in informatics, automation and China

localization requirements will accelerate growth in higher volume segments of sweet spot
to mid-single digits annually
• Mid-term launches of lower-cost platforms for emerging markets and additional IA products
will enable growth to mid- to high-single digits annually
• Long-term innovations in dry slide, additional IA product launches and the development
of modular solutions could accelerate growth to high-single/low-double digits annually
36
Q&A
Point of Care
Strategy
Clarifying Point of Care (POC) Definition and Fit
POC Fit
True POC testing in
near-patient settings
(ER, Phys Office, Home)
Test performed
near patient
Product Design Can be run by
non-lab personnel
Based on Our Low-volume testing in
laboratory settings
Definition of POC Results that are
actionable
Results available
while patient waits Novel biomarker
introductions in
any setting

lines are blurring,

Point of Care
Molecular
Labs
Point of Care Business Unit
TTM Total Revenue, Ex-COVID-191 Sofia Cumulative Net Placements Triage Cumulative Net Placements
$463M ~83K ~13K

(28%) y/y2 +3K y/y +1K y/y

China Other Instruments
6% 5% 1%
EMEA QuickVue
Other 17% 8% 7%
Sofia
48% North
Triage America
28% 81% Recurring
92%
QuickVue
7%
1. Excludes COVID-19 related revenue

2. Growth rates are in constant currency. Decline driven by strong respiratory revenue in 4Q 2020 and BNP assay transition
COVID-19 Was Just the Beginning, Demand for Point of Care Continues to Grow
Growth in Segments We Currently Serve and

COVID-19 Has Become the Launchpad for in Adjacent Areas Targeted for Expansion
Dramatic Expansion and Wide POC Acceptance
$8B Market 7% CAGR 2021 – 2026 CAGR
Care Continues to Move Away From Centralized Settings

+3.2% +8.8%
Blood Gas Rapids

HOSPITAL &
LAB SYSTEMS
MOBILE CLINICS OTC HOME TESTS DRIVE-THROUGH SIDEWALK TENTS AIRPORTS TELEMEDICINE $2,100M (’21) $1,500M (’21)
Benefits & Convenience of POC Have Been Embraced +2.6%

+8.0% +3%
Awareness Demand
IA HbA1c Other Chemistry
Availability Acceptance $800M (’21) $300M (’21) $400M (’21)
Source: Estimated based on 2022 IQVIA Market Book

Our Differentiator
Combined QuidelOrtho with new and unmatched capabilities
Expanded Portfolio New and Emerging Testing Expansive Global Footprint

Deep POC Expertise
and POC Synergies Area Opportunities and Established Channels
• Proven track record in the design of • Address wider range of test volumes • Potential to adapt dry chemistry to • Expanded sales team
affordable and versatile POC and segments of the continuum POC platforms
instruments • Broad global presence
• Multiple immunoassay and molecular • Integration with current IA menu to
• Visual and instrumented lateral flow diagnostic configurations create multimodal analyzers • Customer segment alignment
• Microfluidics • Integrated combinations leverage • Drive penetration and expansion • Better end-user engagement
breadth of QuidelOrtho diagnostic beyond respiratory into adjacent • Strong distribution relationships
• Automated, scalable, low-cost
capabilities POC testing areas
manufacturing
Bring a Broader Menu to More People in More Places

Growth Driving Trajectory
Near-Term (0-18 Months) Mid-Term (18-24 Months) Long-Term (24 Months+)
Secure/Expand RV Business Leverage and Expand Customer Base Novel Platform Developments
• Capitalize on high RSV, flu and COVID-19 Engage Sofia Customer Base to Toxicology
demand in current “tripledemic” Increase Assay Menu Utilization on Sofia
• Leverage Sofia and QuickVue combo panels to Existing Sofia Menu Sofia Growth
secure existing base and drive new placements
Leapfrog/Other Next-Gen Platforms
• Engage key customers and maintain strong OTC • RV tests • GI Assays
position with branded and PL products • Integration of chemistry and other assay
• Strep A capabilities to current IA
• Strep pneumo • Quantitative, sensitive and precise
• Legionella
New Biomarker Opportunities
Cardiovascular Neurodegeneration
Expand and Grow Cardiac Business Toxicology Chronic disease
With U.S. Triage Launches monitoring
Host response
(sepsis, B/V, etc.)
Triage Growth • TriageTrue hsTnI1
• Drive TriageTrue hsTnI1 penetration and • Triage PlGF1 Focus on Key Segments
assay pull-through OUS • Triage Tox panel with fentanyl
• Leverage U.S. commercial synergies to drive
toxicology and cardiac marker adoption Critical Care Primary Home
ER/FSED/UCC Care Testing
1. TriageTrue hsTnl is our high-sensitivity troponin test. Triage PlGF is our placental
growth factor test used for pregnant women with suspected pre-eclampsia
Key Takeaways
• The COVID-19 pandemic accelerated demand, acceptance and adoption for POC
• QuidelOrtho now has the commercial horsepower, customer segment alignment and range
of solutions critical to market leadership in POC
• Significant opportunity to leverage current and future platforms across the portfolio to expand
menu offerings, increase revenue per site and enable penetration into new customer segments
45
Q&A
Strategy
OTC Consumer-Oriented Physician Urgent Surgical Micro- Free- Sexual Small-Medium Large Donor National

lines are blurring,

Point of Care
Molecular
Clinical Labs
Chart is an approximate distribution of testing sites in the U.S. market

Global leader in immunohematology and North America leader

in blood donation testing
Pioneer of blood typing and infectious disease screening

with rich legacy of innovation
Well positioned for growth with existing customer base along

with expansion into new market segments
Source: 2022 IQVIA Market Book

Our Differentiator
Vein to Vein: Spanning the entire Transfusion Medicine continuum
Testing TWICE to Help Ensure Transfusion

Safety & Efficacy
Industry-Leading Accuracy &

Precision From Donor to Patient:
• Minimizes risk at critical points across

the testing journey
• Increases efficiency with cutting-edge

integrated platforms
• Seamlessly connects vital information

with e-Connectivity® Technology
Our Role
The lifeblood, powering the long-term health of QuidelOrtho
Razor Blade Model Generates Continued
118M
Growth With Recurring Revenue Stream
118.5M
Blood donations globally,
and Stable Repeat Customer Base
A Perpetual Need
~354M units transfused
A Perpetual Need
each year.1
Greater
Greater
EMEA
EMEA China
China
2295
2,295 1051
1,051
Stability in Blood Growth in Plasma NA

NA
1716
1,716 Japan
JAPAN
932
932
+2% y/y Market Growth +10-15% y/y Market Growth
LATAM
LATAM
207
ASPAC
ASPAC
468
468
94% Recurring 13-Yr Average

Revenue Stream Customer
Relationship ~6,700 Automated IH Installed Base Globally
• Consistent and sustained revenue
agnostic of public health outbreaks • Stable repeat customer base
• Enables business to seize new • Established and expanding
opportunities, grow and expand global relationships
ORTHO OPTIX™ ORTHO VISION® ORTHO VISION® Max

1. WHO Reader Swift Analyzer Swift Analyzer
Our Drive
A history of firsts that meet evolving market needs
1947 1989 1993 2006 2009 2016 2020
Need:
Need: Need: Need: Need: Need: Rise of infectious disease Need:
Protect Rh-negative women Prevalence of Cost-effective tech that Rise of infectious disease, Millions of lives at risk from HIV requires test for Pandemic caused by
against isoimmunization hepatitis C reduces processing steps Chagas, caused by insects as HIV risk increases both antibody and antigen SARS-CoV-2
Response: Response: Response: Response:

Development of first Introduction of Ortho FDA approval of VITROS COVID-19
blood bank anti-D test BioVue® System VITROS® HIV Solutions
1+2 Assay
Response: Response: Response:

Introduction of the first Launch of the first FDA- CE Mark for HIV Combo
test for detection of licensed blood screening test
hepatitis C antibodies for Chagas disease
Transfusion Medicine Business Unit
TTM Total Revenue Automated IH Installed Base The Global Market Share Leader
$675M ~6.7K 29%

2
+6% y/y1 +4% y/y Ranked #1 globally

Instruments
6%
Other
Donor 17%
Screening
24% China
8% North
America
55%
Immunohematology EMEA Recurring
76% 20% 94%
1. Growth rates are in constant currency

2. Sourced from 2022 IQVIA Market Book
Market Share by Segment

The market is ripe for expansion and growth
2022 TM Revenue Mix 2022 Market Segment IH Market Penetration
Share of Account Number

Donor Screening
Share of Revenue
Immunohematology
$1.3B
TAM
$960M
TAM
QO 39%
QO 15%
QuidelOrtho
IH DS Penetration
• Immunohematology represents 76% of TM revenue • Immunohematology global market share is 39% • High- and ultra-high-volume segments represent the
• Donor Screening Infectious Disease testing represents 24% • Donor Screening global market share 15% greatest opportunity for IH expansion and growth
• Commercial, automated and network market segments

represent the highest revenue opportunity
Answering New Needs and Driving New Growth

New Needs
Diagnostic Access to More People in More Places | Do More With Less | Navigate Complex Global Regulations
Future Growth Drivers
Automated Menu and Assays Donor Screening (DS) Immunohematology (IH) Digital Solutions
Continue to drive retention Expand further into blood Capture patient testing Grow suite of workflow
rates, stickiness and revenue and plasma infectious disease immunohematology market and decision tools to enhance
growth with addition of new and testing markets with next-gen share in ultra-high throughput and menu and automation
improved assays and reagents donor screening technology and semi-auto segment
for global automated platforms automated platform
Near- Long-
Growth Rate term Accelerated Growth Driven by Next-Gen DS and IH Platforms term
Low-single digits High-single digits

Key Takeaways
• Transfusion Medicine is the lifeblood of the organization, powering long-term health with
reliable and recurring revenue
• As the global market leader, we’re well-positioned to address new market needs with
near-term product launches and investments in informatics
• Portfolio expansion will continue to drive customer “stickiness” and revenue growth across
global installed base
• Significant opportunities exist in the high-/ultra-high-volume market segments in both

donor screening (blood and plasma) and immunohematology
56
Q&A
Strategy
Tammi Ranalli, PhD
Molecular Diagnostics Business Unit Leader

lines are blurring,

Point of Care
Labs
Chart is an approximate distribution of testing sites in the U.S. market

Molecular Diagnostics Business Unit
TTM Total Revenue 3-Year Savanna Installed Base Target 3-Year Savanna Revenue Run Rate Target2
$133M >6K >$250M

$21M Ex-COVID-19

Other 1% Instruments
11%
Savanna
EMEA
5%
9%
North
Other America Recurring
95% 90% 89%
1. Excludes COVID-19-related revenue

2. Three years post full U.S. launch
Our Role
High-Growth Business With Unique Ability to Flex Across the Continuum
The Demand is at an All-Time High Unprecedented Need for Flexibility in Testing
$9B Market +9% CAGR Decentralization

Convergence Across Centralization
the Continuum
COVID-19 Elevated Awareness of the Importance

and Value of Molecular Testing
Unrivaled sensitivity
Physicians Small
Hospital
Ultra-high specificity Office Clinic
Sample to answer efficiency & efficacy Need Need Need
Demand is Expanding to Other Areas

Flexible testing panel Precision, quality Low volume testing
sizes & menus & speed during off-shift hours
Disease +12.5% +20.1% +15.2% +10% Most clinically relevant The right combination Plug & play testing
Area Growth results with fewer tests of tests solutions for
2021-2026 decentralized (ER)
CAGR Sexual Health BCID GI Vaginitis options
$700M (’21) $100M (’21) $300M (’21) $200M (’21)
Sample to answer quickly & effectively
Source: Estimated based on 2022 IQVIA Market Book

Our Differentiator
Personalized, Prompt & Precise
Savanna
• Less than 25 minutes from sample to result
without sacrificing quality & performance
• Test Select flexible panel sizes & menus

for personalized patient & segment testing along
with mitigation of reimbursement challenges
• Broader analyte coverage per test run

with higher clinical relevance in fewer cartridges
• Unique menu to drive adoption including syphilis

in the lesion panel and a targeted pharyngitis panel
Built to Answer Needs

Across the Continuum Physicians Office Small Clinic Hospital
From POC to Hospitals
Results in 25 mins Speed and ease-of-use Unique menu
Flexible panels Flexible panels Ease-of-use and

& unique menu flexible panels
Savanna’s Edge vs.

Competitors • Broader analyte coverage across
fewer cartridges
LAB/POC
• No price-prohibitive service Competitor 1
contracts
• Faster time to result
• Faster time to result

• True sample to answer: No hands-on Syndromic
VS Panel
• Test Select offers flexible syndromic Competitor 2
testing
Savanna
• True molecular PCR with higher
sensitivity & accuracy
Rapid POC
• Broader analyte coverage per test run Competitor 3
• Greater ease-of-use
Our Growth Driving Trajectory
Now Available Near-term Long-term (In Development*)
Global Market
Focused Pilot Further Global Penetration & Expansion
Austria
Germany
Italy
EMEA NA LATAM ASPAC
Product Pipeline
Respiratory Viral HSV Panel STI Panel Respiratory Viral GI Panel (Bacterial/Viral) GI Panel (Parasites) Pharyngitis Panel Vaginitis Panel
Panel-4 (RVP4) Panel-11 (RVP11)
• HSV 1 • C. trachomatis • Campylobacter • Cryptosporidium spp. • Group A Strep • T. vaginalis
• Influenza A
• HSV 2 • N. gonorrhoeae • Adenovirus • Shigella spp./EIEC • Giardia lamblia • Strep C/G • C. krusei
• Influenza B
• VZV • M. genitalium • Enterovirus • Salmonella spp. • E. Histolytica • F. necrophorum • L. jensenii
• Respiratory
• Syphilis • T. vaginalis • Human Metapneumovirus • Vibrio spp. • A. haemolyticum • Megaspheara-1
Syncytial Virus
• Influenza A • Sapovirus • Candida spp.
• SARS-CoV-2
• Influenza B • Norovirus • Gardnerella
• Parainfluenza 1, 3 • STEC • A. vaginae
• Parainfluenza 2, 4 • Rotavirus • C. glabrata
• Respiratory Syncytial Virus • Adenovirus • L. crispatus
• Rhinovirus • Yersinia enterocolica • BVAB-3
• Seasonal Coronavirus • C. difficile
*In development and subject to change • SARS-CoV-2 • Astrovirus

Key Takeaways
• Molecular Diagnostics acts as our high-growth business with a unique ability to flex across
the continuum
• The molecular diagnostic market remains a high-growth market beyond COVID-19.

Key segments we are targeting with Savanna include sexual health, vaginitis, GI and other
non-respiratory ID
• Savanna offers personalized, prompt & precise testing. We believe it is well positioned to take
share from older, entrenched platforms and is more attractive to a broader base of customers
• The Savanna projected launch trajectory:

– 2022: Expanded EU in Q4
– 2023: Clinical trials for 6 panels with the U.S. launch of RVP 4 and HSV/VZV
– 2024: Worldwide launch of five additional panels driving placements in a crowded market dominated by
respiratory players (e.g., HSV/VZV with syphilis and bacterial pharyngitis)
65
Q&A
Innovating at the
Speed of Light
Werner Kroll, PhD
Senior Vice President, Research & Development
QuidelOrtho Set to Address Key Market Trends
Trends Implications
1 Decentralization
of care and testing
Rising demand for
diagnostic testing:
Increase of • Manage chronic conditions
2 preventive medicine • New diagnostic tests to support recently
discovered markers Positioned to
Emergence of new take advantage of
3
• Repeated therapy monitoring
treatments & disease • Impact of care at home monitoring market trends and
markers • Point of care, molecular and at-home expand position
Limited skilled resources to

4
Increasing access to Research
Reference
healthcare globally manage the growing demand: Labs
• Greater reliance on
Declining availability automation/simple testing
5 of skilled medical
technologists
• Systems that are easy to use
Hospitals Clinics
• Automation of rule-based testing
6 Increasing digitalization • Support from decision algorithms Point of Care Home

and automation • Broader application of AI
QuidelOrtho Project Pipeline

Phase 0
Ideation
Business Units Phase 1
Feasibility Phase 2
Design Optimization Phase 3 Phase 4/EUAs
V&V/Clinical Regulatory Review & Launch
Labs
Legend
Point of Care
Assay
Instrument
Molecular Software
Diagnostics
Transfusion
Medicine
Launch
Phase 2 Phase 3
Exit Exit
Phase 1
Exit
Phase 0
Exit
Primary and secondary screens

QuidelOrtho Set to Address Key Market Trends
Trends Implications
1 Decentralization
of care and testing
Rising demand for
diagnostic testing:
Increase of • Manage chronic conditions
2 preventive medicine • New diagnostic tests to support recently
discovered markers Positioned to
Emergence of new take advantage of
3
• Repeated therapy monitoring
treatments & disease • Impact of care at home monitoring market trends and
markers • Point of care, molecular and at-home expand position
Limited skilled resources to

4
Increasing access to Research
Reference
healthcare globally manage the growing demand: Labs
• Greater reliance on
Declining availability automation/simple testing
5 of skilled medical
technologists
• Systems that are easy to use
Hospitals Clinics
• Automation of rule-based testing
6 Increasing digitalization • Support from decision algorithms Point of Care Home

and automation • Broader application of AI
QuidelOrtho Project Pipeline

Phase 0
Ideation
Business Units Phase 1
Feasibility Phase 2
Design Optimization Phase 3 Phase 4/EUAs
V&V/Clinical Regulatory Review & Launch
Labs
Legend
Point of Care
Assay
Instrument
Molecular Software
Diagnostics
Transfusion
Medicine
Launch
Phase 2 Phase 3
Exit Exit
Phase 1
Exit
Phase 0
Exit
Primary and secondary screens

71
Q&A
Boosting Growth Through
Commercial Excellence
Michael Iskra
Executive Vice President
& Chief Commercial Officer
Strategic Priorities
Integration and Culture Unite the people, processes and products of QuidelOrtho to accelerate
innovation, expand commercial reach and improve patient outcomes across the healthcare continuum,
within a culture of speed, happiness, and engagement.
Product Innovation Invest in R&D to expand diagnostic testing platforms and menus across the
business portfolios, and secure global clearances for roll-out of innovative instruments and assays.
Commercial Excellence Lead the industry in customer satisfaction and maximize revenue pull-through
with superior quality, differentiated services and steadfast focus on Retain, Grow, Win strategies.
Operational Excellence Integrate global operations and manage supply chains, which are expected to
deliver cost synergies, competitive advantages and revenue targets.
Capital Deployment Leverage strong balance sheet and cash generation to evaluate longer-term
growth investments to potentially increase operational capacity, capture a larger share of the market,
and/or generate more revenue.
Customer Excellence Improves Retention and Promotes Growth

Investing in our foundation for seamless customer experiences and technological
advancements to drive employee satisfaction and customer loyalty
Key Differentiators
#1 in Service 7 Years in a Row

Increased Faster Self Lower Total
2016 2017 2018 2019 2020 2021 2022 Analyzer Issue Service Cost of
Uptime Resolution Capabilities Ownership
QuidelOrtho 1 1 1 1 1 1 1
Company 1 5 5 5 5 5 5 5
Company 2 4 4 4 4 4 3 3
Technology Combined Service Models
Company 3 3 3 2 2 2 2 4
Company 4 2 2 2 3 3 4 2
1. Artificial Intelligence
Leverage Best-in-Class
2. Merged Reality
Processes and Service
3. Virtual Instruction
Around the World
Data is from IMV ServiceTrak™. QuidelOrtho was ranked #1 in overall NPS for the last 7 4. Customer 360
years over the competition. IMV ServiceTrak™ is a third-party blinded study (n = 880),
U.S. Clinical Laboratory customers only.
Commercial Enablement Will Accelerate Growth and Competitive Advancements

Maximizing revenue pull-through with a focused and disciplined go-to-market approach
Level 3
360 Degree
World Class
• Holistic approach across sales and service
• Enhance new customer engagement channels
• Unite entire enterprise and all channels
Level 2
Evolution Continuous Improvement
• Optimize strategy
• Increase sales productivity
• Identify additional growth opportunities
Level 1
Edge Foundational
• Develop position assessment and define sweet spot
• Establish growth equation and focused commercial KPIs
• Enable commercial teams to execute
Extensive Commercial Footprint Drives Global Reach

Global footprint comprised of 2,800+ commercial sales and service teammates
that reach customers in 130+ countries
EMEA
554
NA
1,067
Greater
China
399
LATAM ASPAC*
Market serviced 364 475
by QuidelOrtho
Note: Includes Global Commercial Sales

and Service staff head count as of November
2022. Direct and indirect markets.
*ASPAC includes Japan
Combined QuidelOrtho Portfolio Presents Outsized Market Potential

The strength of our global footprint and combined product bag will enable us to deliver
on our commercial strategy and ambitions
Revenue creation through Enhanced distribution Strengthened global

cross-selling opportunities capabilities customer reach
Identify opportunities to Enable distribution partners to Leverage Ortho’s global sales

cross-sell products given commercialize the QuidelOrtho engine to accelerate
limited overlap in Quidel product bag, unlocking access to sales of Quidel products,
and Ortho customer base additional customers and segments Savanna and Triage
Example markets: U.S., Greater Example markets: Example markets: Brazil, Spain,
China, Germany, Italy U.S., Panama Australia/New Zealand
78
Q&A
Financials
Joe Busky
Chief Financial Officer
QuidelOrtho – Proprietary & Confidential. | © 2022. All Rights Reserved. 80
Key Messages
Multiple growth drivers position QuidelOrtho to sustainably grow at an HSD growth rate
Strong recurring revenue and shifting mix to higher margin segments will enable us
to maintain top-tier margins while investing for growth
Strong balance sheet and cash generation give us the flexibility to allocate funds
toward several capital deployment priorities
3Q 2022 – YTD Results & FY 2022 Guidance Recap1
3Q 2022 – YTD Results Summary
Total Revenue Revenue Growth, Adjusted EBITDA Adjusted EPS

Ex-COVID-192
$3.2B $1.3B3 $11.993
+26% y/y1 +8% y/y3 40.8% margin1 +41% y/y1
FY 2022 Supplemental Combined Guidance Recap
$2.48-2.53B $1.49-1.53B
(+7-9% constant currency) (38.4-38.6% margin)
Total revenue, ex-COVID-19 Adjusted EBITDA
$3.88-3.96B $13.20-13.80
(+6-8% constant currency) Adjusted diluted EPS
Total revenue
1. Includes presentation of supplemental year-to-date third quarter 2022 and 2021 revenues and adjusted operating results as if Quidel and Ortho had been combined for the applicable periods; revenue growth rates are shown on a constant currency
basis; the term “constant currency” means we have translated local currency revenues for all reporting periods to U.S. dollars using internally derived currency exchange rates held constant for each period; this additional non-GAAP financial information
is not meant to be considered in isolation from or as a substitute for financial information prepared in accordance with GAAP. See reconciliation of non-GAAP measures included in the Appendix for reconciliation to closest GAAP metric.
2. Underlying base business reflects constant currency growth, excluding COVID-19 revenue.
3. See reconciliation of non-GAAP measures included in the Appendix for reconciliation to closest GAAP metric.
Ahead of Cost Synergy Target

Identified and started executing on more than $50M in cost synergies
Realized Synergies (partial year):

Duplicative costs: 2023
Board of directors
Executives (CEO, CFO, GC, R&D)
Senior management
>$30M 2024
Other administrative costs
Competitive bidding of contracts: Cumulative
$30M
Insurance (D&O, E&O, P&C) Cost
Audit fees Synergies
Improved supplier agreements:

Consolidated technology agreements
Indirect sourcing consolidation
Travel expense contracts
HR contracts 2025
Future Opportunities:
Commercial and operational optimization: $30M
Distribution efficiencies
Improved supplier agreements
Implementation of best practices
Strong Cash Flow and Balance Sheet Provides Flexibility and Stability
3Q 2022 – YTD Cash Flow1 3Q 2022 Balance Sheet
$679M
Operating Cash Flow1
$284M Cash &
~1.4x
Marketable Securities
$709M Recurring
Net Debt to
Adjusted EBITDA2
Free Cash Flow1
$104M
Capital Expenditures1
$2.7B Total Debt
1. Supplemental combined cash flows and management estimate of recurring free cash flow reflecting operating cash flow less CapEx and $133M in acquisition, integration, and other costs.
2. Based on management estimates for trailing 12-months supplemental combined EBITDA and 3Q 2022 net debt.
Capital Deployment: Strong Balance Sheet and Cash Generation Give Us the
Flexibility to Allocate Funds Toward Several Capital Deployment Priorities
Support menu expansion and development R&D Investment

of innovative new instruments
Manufacturing
Capital investment to increase Capacity Expansion
manufacturing capacity
Debt
Maintain appropriate levels of leverage Paydown
Share
Return capital to shareholders through share repurchases Repurchase
Strategic
Strategic M&A as the right opportunities present themselves M&A
Our Framework for Long-Term Value Creation

Key Business Attributes Long-Term Financial Drivers
Revenue/ Continuous development of new instruments

Pure play IVD company Installed Base while expanding test menus from home to hospital,
with global reach and Growth lab to clinic
industry-leading expertise
in highly attractive,
growing market
Cost synergies and strong investment
EBITDA Margin
in productivity initiatives; grow revenue
Strong differentiation Expansion faster than G&A
with robust instruments,
best-in-class service and
recurring revenue
base for growth Deleveraging is a top priority with goal to
Deleveraging be at or below ~2x net leverage by end of 2024, while
maintaining flexibility for strategic M&A opportunities
Significant investments in
innovation to strengthen
products and services and
expand addressable Near-term focus on integration, but plan to
market M&A be opportunistic in areas with high strategic fit
to provide incremental growth
Attractive Financial Outlook With Expected Strong Growth, Profitability and FCF Generation
$48B Total Addressable Market Delivers 5-7% Steady-State Growth1
1. 2021 market sizes excluding COVID-19 revenue; Sourced from 2022 IQVIA Market Book
Execution of Strategic Priorities Will Position

QuidelOrtho for Strong Revenue and Earnings Growth
Strategic Priorities
3-Year Outlook (2023-2025)
Integration and Culture
6-9%1 27-29% DD CAGR

2025 adjusted Adjusted EPS
Product Innovation above market growth 2019-20254
EBITDA margin
Commercial Excellence 25-50 bps 60-65% $6-7

Adjusted EBITDA Target Adjusted
2025 adjusted EPS5
Margin Expansion2 FCF Conversion3
Operational Excellence
Capital Deployment 1.
2.
Organic revenue CAGR, excluding COVID-19 revenue.
Adjusted EBITDA margin expansion with COVID-19 revenue at an endemic level.
3. Adjusted EBITDA to Adjusted FCF conversion target of 60%-65%; Near-term is expected to be 50%-65% depending on capital investments.
4. Adjusted EPS CAGR without assumed capital deployment beyond required debt paydown.
5. 2025 Adjusted EPS Includes $3.00-$3.50 in depreciation expense.
Growth and Margin Profile Are Misaligned With Valuation
FY 22E-FY 25E Revenue Growth1,3 FY 23E EV/EBITDA Multiple3

QDEL QDEL
Peers Consensus 3-Yr Outlook
16.1x
16.9x
6-9%
7% 6%
11x
FY 23E EBITDA Margin2,3
29% 29%
Peers QDEL Peers QDEL
1. CAGR is based on consensus revenue estimates and excludes estimated COVID-19 revenue
2. Consensus 2023 Adjusted EBITDA margin
3. Source: Nasdaq IR Insight data as of 12/08/2022; Peers include Abbott Laboratories, Bio-Rad Laboratories, BioMerieux SA, DiaSorin SpA, Danaher Corporation, Hologic Inc., PerkinElmer, Qiagen NV, Siemens Healthineers, and Thermo Fisher Scientific
Q&A
quidelortho.com
Appendix
Business Unit Trailing 12-month Revenue
Revenue Excluding COVID-19 Revenue

Trailing 12-months as of 3Q22 and 3Q21
Percent Currency Constant

In millions 2022 2021 Change Impact Currency
Labs $ 1,345.0 $ 1,337.7 0.5% (1.9%) 2.4%
Transfusion Medicine $ 675.3 $ 660.7 2.2% (3.8%) 6.0%
Point-of-Care $ 463.1 $ 644.7 (28.2%) (0.5%) (27.7%)
Molecular Diagnostics $ 20.7 $ 21.6 (4.2%) (0.9%) (3.3%)
Revenue
Trailing 12-months as of 3Q22 and 3Q21
Percent Currency Constant
In millions 2022 2021 Change Impact Currency
Labs $ 1,380.0 $ 1,421.9 (2.9%) (1.7%) (1.2%)
Transfusion Medicine $ 675.3 $ 660.7 2.2% (3.8%) 6.0%
Point-of-Care $ 2,154.3 $ 1,580.8 36.3% (0.4%) 36.7%
Molecular Diagnostics $ 133.0 $ 245.9 (45.9%) (0.1%) (45.8%)
1. The table above includes Ortho revenues in historical periods. The term “constant currency” means we have translated local currency revenues for all reporting periods to U.S. dollars using currency exchange rates held constant
for each period; this additional non-GAAP financial information is not meant to be considered in isolation from or as a substitute for financial information.
Supplemental Combined Revenue by Business Unit (Year-to-Date)1
Year to date
Percent Currency Constant Less: COVID-19 Constant Currency (a)

In millions 3Q 2022 3Q 2021 Change Impact revenue impact
Currency (a)
ex COVID-19 revenue
Labs $ 1,016.5 $ 1,060.0 (4.1)% (2.3)% (1.8)% 3.1% 1.3%
Transfusion Medicine 505.6 494.5 2.2% (4.6)% 6.8% —% 6.8%
Point-of-Care 1,580.5 879.5 79.7% (0.8)% 80.5% (42.5)% 38.0%
Molecular Diagnostics 82.1 149.5 (45.1)% (0.2)% (44.9)% 63.2% 18.3%
Total supplemental combined revenues $ 3,184.7 $ 2,583.5 23.3% (2.2)% 25.5% (17.1)% 8.4%
1. The table above includes Ortho revenues as if the acquisition had occurred on January 4, 2021. The term “constant currency” means we have translated local currency revenues for all reporting periods to U.S. dollars using
currency exchange rates held constant for each period; this additional non-GAAP financial information is not meant to be considered in isolation from or as a substitute for financial information.
Non-GAAP Reconciliations – Adjusted Net Income

Year to date
In millions, except per share data 3Q 2022 Diluted EPS 3Q 2021 Diluted EPS
Net income $ 518.4 $ 9.56 $ 412.9 $ 9.72
Adjustments:
Amortization of intangibles 78.6 20.5
Acquisition and integration costs 109.6 1.8
Loss on extinguishment of debt 24.0 —
Unwind inventory fair value adjustment 46.6 —
Incremental depreciation on PP&E fair
1.3 —
value adjustment
Noncash interest expense for deferred
2.3 3.6
consideration
Amortization of deferred cloud computing
3.9 2.9
implementation costs
Derivative mark-to-market gain (4.4) —
Loss (gain) on investments 0.8 (1.2)
Employee compensation charges and other costs 1.8 —
EU medical device regulation transition costs 1.0 —
Change in fair value of acquisition contingencies 0.1 0.1
Income tax impact of adjustments (46.5) (5.9)
Discrete tax items 0.6 —
(a)
Adjusted net income $ 738.1 $ 13.62 $ 434.7 $ 10.23
Ortho pre-combination adjusted net income 77.2 145.5
(b)
Supplemental combined adjusted net income $ 815.3 $ 11.99 $ 580.2 $ 8.53
Unless otherwise noted, dollars are at actual foreign exchange rates.

(a) Adjusted net income includes Ortho activities from May 27, 2022 through October 2, 2022.
(b) Supplemental combined Adjusted net income for the current and prior year periods includes the results of historical Ortho and does not include any pro forma adjustments required under Regulation S-X Article 11 or ASC 805.
Non-GAAP Reconciliations – Adjusted EBITDA

Year to date
In millions 3Q 2022 3Q 2021
Net income $ 518.4 $ 412.9
Depreciation and amortization 167.0 37.3

Interest expense, net 41.0 4.7
Provision for income taxes 176.4 112.1
Loss on extinguishment of debt 24.0 —
Employee compensation charges and other costs 1.8 —
Acquisition and integration costs 109.6 1.8
Unwind inventory fair value adjustment 46.6 —
Derivative mark-to-market gain (4.4) —
EU medical device regulation transition costs 1.0 —
Loss (gain) on investments 0.8 (1.2)
Amortization of deferred cloud computing
3.9 2.9
implementation costs
Tax indemnification income (0.3) —
Change in fair value of acquisition contingencies 0.1 0.1
Adjusted EBITDA (a) $ 1,085.9 $ 570.6
Ortho pre-combination Adjusted EBITDA 212.5 420.5
Supplemental combined Adjusted EBITDA (b) $ 1,298.4 $ 991.1
Supplemental combined revenues $ 3,184.7 $ 2,583.5

Adjusted EBITDA margin 40.8% 38.4%
Unless otherwise noted, dollars are at actual foreign exchange rates.

(a) Adjusted EBITDA includes Ortho activities from May 27, 2022 through October 2, 2022.
(b) Supplemental combined Adjusted EBITDA for the current and prior year periods includes the results of historical Ortho and does not include any pro forma adjustments required under Regulation S-X Article 11 or ASC 805.
quidelortho.com

QDEL IR Day Presentation Final 2022.12.13

Uploaded by

Document Information

Original Description:

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

QDEL IR Day Presentation Final 2022.12.13

Uploaded by

Copyright:

Available Formats

December 13, 2022

Supplemental Combined Financial Measures and Non-GAAP Financial Measures

Objectives for Today

• Strong Business: We are an in vitro diagnostics leader with growth opportunities

Who You’ll Hear From Today

Tammi Ranalli, PhD

To Deliver Our Integration Goals, Our Program Is Structured to …

RETAIN & DRIVE HARMONIZE &

Overall Integration Goal Is to Create a Company of Purpose That Enriches and

The QuidelOrtho Way

We are committed to our employees FIRST and we prioritize

We operate with speed by focusing on the few things that matter

We give back to our communities and build enduring customer

Manufacturing and Distribution

*ASPAC includes Japan

How Our Employees Are Feeling

Overall Favorability Trending Positive: Agility

Source: 1. Bank My Cell 2. Data Reportal

As many people over

Source: 1. Deloitte Insights 2. Healthcare Radius 3. World Health Organization

Source: 1. MedTech Drive

Our Industry Is At An Inflection Point

EXPANDING FOR CONVERGENCE ACROSS CONSOLIDATING

lines are blurring,

38x More virtual care visits

10.8% 2022-2029 Projected

QuidelOrtho Is Setup to Meet These Opportunities

EXPANDING FOR CONVERGENCE ACROSS CONSOLIDATING

lines are blurring,

Each Business Unit Operates Within a Large Area of Opportunity

Clinical Immunoassay Molecular Transfusion

$8B $9B $19B $9B $2B

1. Estimated based on 2022 IQVIA Market Book

Introducing Our Business Unit and R&D Executives

EXPANDING FOR CONVERGENCE ACROSS CONSOLIDATING

lines are blurring,

Labs Business Unit

$1.35B ~14K ~4K

Product Lines1 Geography1 Category1

1. Excludes COVID-19-related revenue

Labs Inflection Point: Our Expansive Product Portfolio Ensures Labs

1. CDC, Division of Lab Systems

Lab Market Is Robust and Projected to Grow at ~4% (Clinical Chemistry)

Projected to Grow at 6% CAGR

Low 12% 10% 1%

Clinical Labs Revenue Mix vs. Market Segment Mix

2021 CL Revenue Mix1 2021 Segment Data2

Strength in clinical chemistry Opportunity in larger, faster growing

Installed Base Penetration Within Sweet Spot

Non-Hospital Hospital Volume Annual Standalone CC Integrated Standalone IA Integrated

Product Development Driving Trajectory

~2023 ~2024 ~2025 - 2030

Refresh VITROS Systems Low-Cost, Low-Volume Platforms

Scalable Dry Slide and Development

China Localization Strategy and

• Near-term product launches and investments in informatics, automation and China

Clarifying Point of Care (POC) Definition and Fit

EXPANDING FOR CONVERGENCE ACROSS CONSOLIDATING

lines are blurring,

Point of Care Business Unit

$463M ~83K ~13K

Product Lines1 Geography1 Category1